Akèy › Kansè poumon › Pennsylvania › Pittsburgh
Etid klinik pou Kansè poumon nan Pittsburgh, PA
23 etid pou Kansè poumon ap chèche patisipan nan sit nan ak bò kote Pittsburgh (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Ap rekriteFaz 3
- UPMC-Saint Margaret, Pittsburgh
- UPMC-Mercy Hospital, Pittsburgh
- UPMC Hillman Cancer Center, Pittsburgh
- ak 11 plis
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Ap rekriteFaz 1/2
- University of Pittsburgh Medical Center, Pittsburgh
Distance-Based Exercise to Preserve Function and Prevent Disability
Ap rekrite
- UPMC Hillman Cancer Center, Pittsburgh
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
Ap rekriteFaz 3
- Bryn Mawr Hospital, Bryn Mawr · 11 mi lwen
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Ap rekriteFaz 3
- Bryn Mawr Hospital, Bryn Mawr · 11 mi lwen
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Ap rekriteFaz 3
- UPMC Hillman Cancer Center, Pittsburgh
- Bryn Mawr Hospital, Bryn Mawr · 11 mi lwen
- UPMC Hillman Cancer Center - Monroeville, Monroeville · 11 mi lwen
- ak 1 plis
A Registry for People With Lung Cancer
Ap rekriteEtid obsèvasyon
- ALLEGHENY HEALTH NETWORK (Data Collection Only), Pittsburgh
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
Ap rekriteFaz 2
- Research Site, Pittsburgh
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Ap rekriteFaz 1/2
- Allegheny Health Network, Pittsburgh
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Ap rekriteFaz 2/3
- West Penn Allegheny Health, Pittsburgh
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
Ap rekriteFaz 1/2
- UPMC Hillman Cancer Center, Pittsburgh
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Ap rekriteFaz 3
- Allegheny Cancer Center, Pittsburgh
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Ap rekriteFaz 3
- UPMC Hillman Cancer Center, Pittsburgh
Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation
Ap rekriteFaz 1/2
- UPMC Hillman Cancer Center, Pittsburgh
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
Ap rekriteFaz 1/2
- Allegheny Research Institute (Melanoma/NSCLC), Pittsburgh
Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
Ap rekriteFaz 1
- UPMC Hillman Cancer Center, Pittsburgh
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Ap rekriteFaz 1/2
- UPMC Hillman Cancer Center, Pittsburgh
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
Ap rekriteFaz 2
- Allegheny General Hospital, Natrona Heights · 19 mi lwen
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
Ap rekriteFaz 1/2
- UPMC Hillman Cancer Center, Pittsburgh
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Ap rekriteFaz 2
- UPMC-Saint Margaret, Pittsburgh
- UPMC-Mercy Hospital, Pittsburgh
- University of Pittsburgh Cancer Institute (UPCI), Pittsburgh
- ak 11 plis
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Ap rekriteFaz 2/3
- UPMC-Saint Margaret, Pittsburgh
- University of Pittsburgh Cancer Institute (UPCI), Pittsburgh
- UPMC-Passavant Hospital, Pittsburgh
- ak 9 plis
The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
Ap rekriteEtid obsèvasyon
- Allegheny Health Network, Pittsburgh
Detection of Genetic Markers of Lung Cancer
Ap rekriteEtid obsèvasyon
- Hillman Cancer Center, Pittsburgh
Etid Kansè poumon nan lòt vil
- Houston, TX78 etid
- Boston, MA62 etid
- New York City, NY60 etid
- Los Angeles, CA45 etid
- Washington, DC41 etid
- Arlington, VA41 etid
- Chicago, IL41 etid
- Nashville, TN40 etid
- Baltimore, MD40 etid
- St. Louis, MO39 etid
- Columbus, OH37 etid
- Philadelphia, PA36 etid
Lòt etid nan Pittsburgh
- Kansè Poumon ki pa ti selil48 etid
- Kansè (tout kalite)41 etid
- Kansè nan tete39 etid
- Kansè kolorektal32 etid
- Kansè Metastatik31 etid
- Melanom31 etid
- Kansè ovè30 etid
- Kansè Endomèt23 etid
- Kansè pwostat23 etid
- Akidan serebavaskilè22 etid
- Karsinòm selil skuamèz tèt ak kou22 etid
- Depresyon22 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.